Source: Annual Congress 2009 - Pulmonary circulation II



Rating:

Share or cite this content

Citations should be made in the following way:
O. Korolkova (Voronezh, Russian Federation). Lung hypertension: developmental mechanisms and assesment therapeutic action efficiency. Eur Respir J 2009; 34: Suppl. 53, 3929

Member's Comments

No comment yet.

Related content which might interest you: Asthma and pulmonary arterial hypertension: Two phenotypes sharing a key underlying mechanism Source: Annual Congress 2010 - New mechanisms in lung development, acute and chronic lung diseases Year: 2010 Clinical and pathophysiological features of asthma phenotypes Source: Annual Congress 2013 –Asthma at the bedside Year: 2013 Clinical dyspnoea: brain mechanisms and their clinical impact on brain functions Source: International Congress 2018 – State of the art session: Sleep and breathing disorders Year: 2018 Lung transplantation for pulmonary hypertension: the impact of new drug therapies Source: Annual Congress 2004 - Lung transplantation: new insights in advanced lung disease and new drug developments - do they impact on selection criteria? Year: 2004 Anthracosis of lung: evaluation of potential underlying causes Source: Eur Respir J 2005; 26: Suppl. 49, 304s Year: 2005 Therapeutic approaches to lung aging Source: International Congress 2016 – The future is now: the challenge of ageing in respiratory medicine Year: 2016 Underlying mechanisms and pharmacological approaches for treatment of sarcopenia Source: Virtual Congress 2021 – Sarcopenia in chronic respiratory disease: new definitions, assessment and treatment options Year: 2021 Functional Respiratory Imaging as a sensitive biomarker to assess therapeutic interventions in lung diseases Source: International Congress 2015 – Functional and imaging techniques for assessing lung, airway and respiratory muscles Year: 2015 Endothelial progenitors in pulmonary hypertension: new pathophysiology and therapeutic implications Source: Eur Respir J 2010; 35: 418-425 Year: 2010 Cardiovascular disease: pathophysiological mechanisms Source: Eur Respir Monogr 2015; 67: 37-50 Year: 2015 COPD mechanisms: novel aspects and implications for new therapies Source: ERS Live 2007 Year: 2007 Improving physical activity in lung disease: strategies and importance Source: Annual Congress 2009 - Cournand Lecture Year: 2009 Oral presentation: Potential of ACE2 as a therapeutic target for pulmonary hypertension Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung Year: 2010 Asthma and pulmonary arterial hypertension: do they share a key mechanism of pathogenesis? Source: Eur Respir J 2010; 35: 730-734 Year: 2010 Fibrocytes: potential new therapeutic targets for pulmonary hypertension? Source: Eur Respir J 2010; 36: 1232-1235 Year: 2010 Lung function evaluation in heart failure: possible pitfalls Source: Breathe, 16 (1) 190316; 10.1183/20734735.0316-2019 Year: 2020 Effect of drugs with pleiotropic properties on tone of pulmonary arteries and bronchi in obstructive lung pathology model Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Asthma and diabetes type 2 and their co-existence: Possible changes in lung function and their importance Source: International Congress 2016 – Notable abstracts on clinical problems related to asthma Year: 2016 Molecular endpoints for establishing target engagement by novel idiopathic pulmonary fibrosis therapies Source: Eur Respir J, 53 (3) 1900283; 10.1183/13993003.00283-2019 Year: 2019 Monitoring of pulmonary function in Pompe disease: a muscle disease with new therapeutic perspectives Source: Eur Respir J 2005; 26: 984-985 Year: 2005